ST
STRIDE.AI Strategy view
Competitive position and rollout
Strategy

Why this product exists, why it wins, and how it rolls out.

This route closes the remaining investor and stakeholder gaps from the deck: competitive differentiation, commercialization path, and phased roadmap.

Competitive advantage

Built for translational governance, not generic workflow admin.

The product differentiates itself by combining evaluation, governance, and healthcare-specific translational logic in one operating surface.

Structured scoring

More legible than traditional review panels

STRIDE.AI makes translational readiness explicit instead of leaving it trapped inside expert panel intuition.

Healthcare-specific AI

More relevant than generic project management tools

The platform is framed around clinical, regulatory, IP, technical, and commercial translation rather than generic task tracking.

Portfolio governance

More durable than one-time evaluation tools

STRIDE.AI continues after the award decision with milestone, stage-gate, and institutional risk visibility.

Comparison

Capability matrix

This is the web version of the deck comparison table, simplified into the capabilities that matter most for the first commercial narrative.

Capability Traditional panels Generic PM tools STRIDE.AI
Structured scoring
Partial
No
Yes
TRI index
No
No
Yes
Risk heatmaps
Partial
No
Yes
Optimization guidance
No
Partial
Yes
Portfolio governance
Partial
Partial
Yes
Healthcare-specific AI
No
No
Yes
Stage-gate modelling
No
Partial
Yes
Commercialisation model

Development to spin-out

01
Duke-NUS development foundation
02
Exclusive licence pathway
03
Spin-out commercialisation
Rollout roadmap

12-month phased build

Phase 1 Months 1–6
Evaluation engine and TRI scoring
Phase 2 Months 7–12
Portfolio governance and commercialization tooling
Phase 3 Year 2+
Regional scale and institutional deployment
Strategy route for competitive advantage, capability matrix, and rollout planning.